Literature DB >> 17692000

Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention.

Ben Boursi1, Nadir Arber.   

Abstract

In the third millennium preventive medicine is becoming a corner stone in our concept of health. Colorectal cancer (CRC) fits the criteria of a disease suitable for prevention interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases and 500,000 deaths annually. CRC has a natural history of transition from precursor to malignant lesion that spans, on average, 10-15 years, providing a window of opportunity for effective interventions and prevention. Indeed, CRC is preventable in up to 90% of the cases. Simple life style modifications (balanced diet avoidance of smoking and alcohol, and moderate physical activity) can prevent up to 50% of the cases of colorectal cancer. Compliance with current screening methods is a major barrier to the achievement of optimal results, a large part of the average risk population has not been screened by any method. Several newly developed screening modalities, such as the virtual colonoscopy and stool genetic testing may improve compliance. In addition, chemoprevention, a new science that has emerged during the last decade, presents an alternative approach to reducing mortality from colorectal cancer as well as other cancers. Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel. In light of the recent evidence of the efficacy of chemoprevention in persons at high risk for CRC cancer, it seems only appropriate to consider similar strategies for the general population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692000     DOI: 10.2174/138161207781368783

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

1.  Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules.

Authors:  Balaiya Velmurugan; Subhash Chander Gangar; Manjinder Kaur; Alpna Tyagi; Gagan Deep; Rajesh Agarwal
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

Review 2.  Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.

Authors:  Peng Li; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2010-08-11       Impact factor: 4.742

3.  A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women.

Authors:  Harvey J Murff; Xiao-Ou Shu; Honglan Li; Qi Dai; Asha Kallianpur; Gong Yang; Hui Cai; Wanqing Wen; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

4.  CYP1B1 Leu432Val polymorphism and colorectal cancer risk among Caucasians: a meta-analysis.

Authors:  Yong Xie; Guo-Qing Liu; Xiong-Ying Miao; Yi Liu; Wei Zhou; De-Wu Zhong
Journal:  Tumour Biol       Date:  2011-12-22

5.  Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.

Authors:  Dhimant Desai; SubbaRao V Madhunapantula; Krishnegowda Gowdahalli; Arati Sharma; Raghavendragowda Chandagaludoreswamy; Karam El-Bayoumy; Gavin P Robertson; Shantu Amin
Journal:  Bioorg Med Chem Lett       Date:  2009-09-22       Impact factor: 2.823

6.  Cardiovascular medication use and risk for colorectal cancer.

Authors:  Denise M Boudreau; Elizabeth Koehler; Stephen J Rulyak; Sebastien Haneuse; Robert Harrison; Margaret T Mandelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-28       Impact factor: 4.254

7.  Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc.

Authors:  Feng-Hou Gao; Xiao-Hui Hu; Wei Li; Hua Liu; Yan-Jie Zhang; Zhu-Ying Guo; Mang-Hua Xu; Shi-Ting Wang; Bin Jiang; Feng Liu; Ying-Zheng Zhao; Yong Fang; Fang-Yuan Chen; Ying-Li Wu
Journal:  BMC Cancer       Date:  2010-11-06       Impact factor: 4.430

8.  Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.

Authors:  Kim Vaiphei; Aruna Rangan; Rajinder Singh
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

9.  Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats.

Authors:  Balaiya Velmurugan; Rana P Singh; Alpna Tyagi; Rajesh Agarwal
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

Review 10.  Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk.

Authors:  Derek V Seidel; M Andrea Azcárate-Peril; Robert S Chapkin; Nancy D Turner
Journal:  Semin Cancer Biol       Date:  2017-07-01       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.